MedPath

Naltrexone

Generic Name
Naltrexone
Brand Names
Contrave, Embeda, Vivitrol
Drug Type
Small Molecule
Chemical Formula
C20H23NO4
CAS Number
16590-41-3
Unique Ingredient Identifier
5S6W795CQM
Background

Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.

Indication

Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.

Associated Conditions
Alcohol Dependency, Cholestatic pruritus, Obesity, Opioid Dependence, Severe Pain
Associated Therapies
-
Clinical Trials
Related News

Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder

Phase 2
Not yet recruiting
Conditions
Opioid Dependence
Interventions
Drug: Vivitrol
Drug: Brixadi
First Posted Date
2020-07-01
Last Posted Date
2024-11-01
Lead Sponsor
University of Pennsylvania
Target Recruit Count
200
Registration Number
NCT04454411

Low-dose Naltrexone for Bladder Pain Syndrome

Phase 2
Suspended
Conditions
Bladder Pain Syndrome
Interstitial Cystitis
Interventions
Drug: Placebo
Drug: Naltrexone
First Posted Date
2020-06-29
Last Posted Date
2023-12-22
Lead Sponsor
Stanford University
Target Recruit Count
40
Registration Number
NCT04450316
Locations
🇺🇸

Stanford Health Care, Stanford, California, United States

Effect of Naltrexone in Achieving and Maintaining Abstinence From Alcohol in Patients With Cirrhosis.

Not Applicable
Completed
Conditions
Liver Cirrhosis
Interventions
Drug: Placebo oral tablet
Drug: Naltrexone
First Posted Date
2020-05-18
Last Posted Date
2023-03-28
Lead Sponsor
Institute of Liver and Biliary Sciences, India
Target Recruit Count
100
Registration Number
NCT04391764
Locations
🇮🇳

Institute of Liver and Biliary Sciences, New Delhi, Delhi, India

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

Phase 2
Terminated
Conditions
Acute Respiratory Distress Syndrome
Severe Acute Respiratory Syndrome (SARS)
COVID-19
Coronavirus Infections
Interventions
Other: Placebo
Drug: Naltrexone
Drug: Ketamine
First Posted Date
2020-04-28
Last Posted Date
2022-01-26
Lead Sponsor
William Beaumont Hospitals
Target Recruit Count
70
Registration Number
NCT04365985
Locations
🇺🇸

William Beaumont Hospital, Royal Oak, Michigan, United States

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

Phase 2
Withdrawn
Conditions
Pruritus
Atopic Dermatitis
Dermatitis
Pruritus Chronic
Interventions
Drug: Naltrexone
Other: Placebo
First Posted Date
2020-03-30
Last Posted Date
2023-04-04
Lead Sponsor
University of Minnesota
Registration Number
NCT04325802
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

Phase 4
Recruiting
Conditions
Major Depressive Disorder
Depression
Interventions
Drug: Buprenorphine
Drug: Naltrexone
Drug: Oral Placebo
Drug: IM Placebo
Device: Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.
First Posted Date
2020-02-19
Last Posted Date
2024-07-03
Lead Sponsor
Marta Peciña, MD PhD
Target Recruit Count
120
Registration Number
NCT04276259
Locations
🇺🇸

Bellefield Tower, Pittsburgh, Pennsylvania, United States

A Novel Human Lab Model for Screening AUD Medications

Phase 2
Completed
Conditions
Alcohol Use Disorder
Interventions
Drug: Varenicline
Drug: Naltrexone
Drug: Placebo
First Posted Date
2020-01-31
Last Posted Date
2023-09-14
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
53
Registration Number
NCT04249882
Locations
🇺🇸

UCLA Addictions Lab, Los Angeles, California, United States

Opioids and Social Support Enhanced Extinction Effects

Early Phase 1
Conditions
Fear
Interventions
Drug: Placebo
Drug: Naltrexone
First Posted Date
2019-11-18
Last Posted Date
2025-01-06
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
60
Registration Number
NCT04166071
Locations
🇺🇸

UCLA Department of Psychology, 5514 Pritzker Hall, Los Angeles, California, United States

🇺🇸

UCLA, Los Angeles, California, United States

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

Phase 2
Withdrawn
Conditions
Atopic Dermatitis
Pruritus
Dermatitis
Interventions
Other: Placebo Cream
Drug: Naltrexone
First Posted Date
2019-11-06
Last Posted Date
2021-04-20
Lead Sponsor
University of Minnesota
Registration Number
NCT04154033
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis

Phase 2
Withdrawn
Conditions
Osteoarthritis
Arthritis, Rheumatoid
Arthritis, Psoriatic
Interventions
Drug: Naltrexone
Drug: Placebo
First Posted Date
2019-10-03
Last Posted Date
2020-01-09
Lead Sponsor
Brigham and Women's Hospital
Registration Number
NCT04115020
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy